CPS
The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program
The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program uses in-depth content, engaging activities, and comprehensive cases to help you confidently:
- Understand the core principles of PD-L1 pathology
- Learn the process for evaluating stained specimens for PD-L1 expression
- Recognize confounding considerations that affect PD-L1 interpretation
- Score images for PD-L1 expression across a variety of patient samples
The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program
Triple-Negative Breast Cancer (TNBC)
PD-L1 is a proven biomarker in triple-negative breast cancer. Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).
Head and Neck Squamous Cell Carcinoma (HNSCC)
PD-L1 is a proven biomarker in head and neck squamous cell carcinoma (HNSCC). Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).
Cervical Cancer
PD-L1 is a proven biomarker in cervical cancer. Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).
Esophageal Squamous Cell Carcinoma (ESCC)
PD-L1 is a proven biomarker in esophageal squamous cell carcinoma (ESCC). Learn how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).
D63233/04